摘要
目的探讨替格瑞洛联合盐酸川芎嗪对不稳定型心绞痛(unstable angina pectoris,UAP)患者内皮细胞特异性分子-1(endothelial cellspecific molecule-1,ESM-1)、白介素-1β(interleukin-1β,IL-1β)、可溶性血管细胞黏附分子1(soluble vascular cell adhesion molecule 1,sICAM-1)的影响。方法选择2019年2月至2020年2月于华中科技大学同济医学院附属协和医院呼吸与危重症医学科接受治疗的113例UAP患者,采用随机数表法分为联合组(盐酸川芎嗪+替格瑞洛,n=57)及单药组(替格瑞洛,n=56)。两组均以14 d为1个疗程,共治疗2个疗程。比较两组临床疗效、血清ESM-1、IL-1β、sICAM-1、纤维蛋白原(fibrinogen,FBG)、D-二聚体(D-Dimer,D-D)、纤维蛋白降解产物(fibrinogen degradation product,FDP)、临床症状及不良反应发生情况。结果治疗后,联合组总有效53例(92.98%),单药组总有效44例(78.57%),两组总有效率比较差异有统计学意义(P<0.05)。两组血清ESM-1、IL-1β、sICAM-1、D-D及FDP水平均较治疗前下降,且联合组低于单药组,差异有统计学意义(P<0.05)。两组FBG水平较治疗前升高,且联合组高于单药组(P<0.05)。两组不良反应总发生率差异无统计学意义(P>0.05)。结论在UAP患者中应用替格瑞洛联合盐酸川芎嗪效果显著,可有效改善患者血清ESM1、IL-1β、sICAM-1水平,且安全性较佳。
Objective To study the effects of ticagrelorcombined with ligustrazine hydrochloride on endothelial cell specific molecule-1(ESM-1),interleukin-1β(IL-1β)andsoluble vascular cell adhesion molecule 1(sICAM-1)in patients with unstable angina pectoris(UAP).Methods A total of 113 patients with UAP treated in the department of respiratory and critical care medicine,union hospital,Tongji medical college,Huazhong university of science and technologyfrom February 2019 to February 2020 were selected and divided into combination group(ticagrelor+ligustrazine hydrochloride,n=57)and monotherapy group(ticagrelor,n=56)by random number table method.Both groups took 14 days as a course of treatment,and two courses of treatment were performed in both groups.The clinical efficacy,serum ESM-1,IL1β,sICAM-1,fibrinogen(FBG),D-dimer(D-D),fibrinogen degradation products(FDP),clinical symptoms and adverse reactions were compared between the two groups.Results After treatment,the total effective rate was 53 cases(92.98%)in the combined group and 44 cases(78.57%)in the single drug group,and there was significant difference in the total effective rate between the two groups(P<0.05).Serum ESM-1,IL-1β,sICAM-1,D-D and FDP in the two groupsdecreased,and the levels in the combined group were significantly lower than those in the single drug group(P<0.05).The levels of FBG in the two groups increased,and the levels in the combined group were significantly higher than those in the single drug group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion In patients with UAP,ticagrelor combined with ligustrazine hydrochloride has a significant effect,which can effectively improve the serum levels of ESM-1,IL-1βand sICAM-1,which also has good security.
作者
杨丹
许娟娟
王璇
李云云
朱启明
YANG Dan;XU Juanjuan;WANG Xuan;LI Yunyun;ZHU Qiming(Department of Respiratory and Critical Care Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei 430022,Wuhan Province,China;Department of Cardiovascular Medicine,Hankou District,General Hospital of the Central Theater of the Chinese People's Liberation Army,Wuhan 430012,Wuhan Province,China)
出处
《世界临床药物》
2022年第1期51-55,共5页
World Clinical Drug
